Search Results
Search for other papers by Carolina C Marques in
Google Scholar
PubMed
Search for other papers by Angelo B Brito in
Google Scholar
PubMed
Search for other papers by Eduardo N Lima in
Google Scholar
PubMed
Search for other papers by Mauro D Donadio in
Google Scholar
PubMed
Search for other papers by Rachel Pimenta Riechelmann in
Google Scholar
PubMed
Background: 177-LuDOTATE is an effective but expensive treatment for neuroendocrine tumors (NETs). Reducing treatment-related costs, such as the number of images, could improve access of 177-LuDOTATE. We evaluated early radiological tumor progression and prognostic factors in pts with NETs treated with 177-LuDOTATE.
Methods: We retrospectively included all pts with NETs who received at least one cycle of 177-LuDOTATE. The primary endpoint was the rate of early radiological progression between cycles 2 and 3 (in 10 - 16 weeks). Secondary endpoints were progression-free survival (PFS) and overall survival (OS) according to prognostic factors (tumor grade, primary site, functioning syndrome, 177-LuDOTATE treatment line) in Cox proportional hazards models.
Results: The median number of 177-LuDOTATE cycles was 3 (range 1-6) among 59 patients included. Ten (17%) patients had early progression. Among 14 patients who received ≤ 2 cycles of 177-LuDOTATE, 10 (72%) stopped treatment due to disease progression, with 5 patients having a G2 (ki67: 5-25%) and 4, a G3 (ki67: 25-90%) NET. In the Cox multivariable analysis, higher grade (G2 or G3 vs G1) were significantly associated with inferior PFS and OS. The median PFS of G1, G2 and G3 NET pts were: 34.1, 11.7 and 6.1 months (p = 0.01), respectively.
Conclusions: It is feasible to perform imaging tests after 177-LuDOTATE completion for patients with indolent NETs, with the intent to reduce costs. For patients with more aggressive disease, such as those with higher G2 and G3 NETs, we advise to perform more frequent images during 177-LuDOTATE therapy.
